Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSF-173 for induced excessive sleepiness in healthy volunteers
2006-007074-29Phase 2Active
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VSF-173 in Excessive Daytime Sleepiness (EDS) (4 arms), sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Maintenance of Wakefulness Test average latency. Started Mar 2007; status: active.
02
Drugs
VSF-173
03
Conditions
Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on 2006-007074-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007074-29.